/ALDX
ALDX Stock - Aldeyra Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$4.96-1.00%
$0.05 (-1.00%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.61
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+41.1%upside
Target: $7.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALDX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.91 – $5.01
TARGET (TP)$7.00
STOP LOSS$4.56
RISK/REWARD1:5.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.82
52W High$7.20
52W Low$1.14
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-56,221 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-60,117,032 | $-42,794,083 | $-62,679,987 | $-56,219,536 | $-34,666,755 |
| Net Income | $-55,851,444 | $-37,542,510 | $-62,024,636 | $-57,776,274 | $-37,553,729 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.94 | $-0.64 | $-1.06 | $-1.07 | $-1.11 |
Company Overview
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$12
Average Target
↑ 135.2% Upside
Now
$10
Low
$12
Average
$15
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 3rd 2024 | Oppenheimer | Upgrade | Outperform | $10 |
| April 2nd 2024 | H.C. Wainwright | Resumed | Buy | $10 |
| April 27th 2022 | H.C. Wainwright | Resumed | Buy | $15 |
Earnings History & Surprises
ALDXBeat Rate
72%
Last 18 quarters
Avg Surprise
+8.4%
EPS vs Estimate
Beats / Misses
13/4
1 met exactly
Latest EPS
$-0.13
Q4 2025
EPS Surprise History
Q1 24
+61.9%
$-0.08vs$-0.21
Q2 24
-75.0%
$-0.14vs$-0.08
Q3 24
-100.0%
$-0.28vs$-0.14
Q4 24
0.0%
$-0.25vs$-0.25
Q1 25
-8.0%
$-0.27vs$-0.25
Q2 25
+32.0%
$-0.17vs$-0.25
Q3 25
+23.8%
$-0.16vs$-0.21
Q4 25
+23.5%
$-0.13vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 27, 2026 | $-0.14 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.17 | $-0.13 | +23.5% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.21 | $-0.16 | +23.8% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.25 | $-0.17 | +32.0% | ✓ BEAT |
Q1 2025 | Feb 28, 2025 | $-0.25 | $-0.27 | -8.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.25 | $-0.25 | 0.0% | = MET |
Q3 2024 | Aug 1, 2024 | $-0.14 | $-0.28 | -100.0% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-0.08 | $-0.14 | -75.0% | ✗ MISS |
Q1 2024 | Mar 7, 2024 | $-0.21 | $-0.08 | +61.9% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-0.24 | $-0.14 | +41.7% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.31 | $-0.15 | +51.6% | ✓ BEAT |
Q2 2023 | May 4, 2023 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q1 2023 | Mar 9, 2023 | $-0.34 | $-0.22 | +35.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.34 | $-0.25 | +26.5% | ✓ BEAT |
Q3 2022 | Aug 5, 2022 | $-0.32 | $-0.30 | +6.3% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.31 | $-0.29 | +6.5% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $-0.29 | $-0.27 | +6.9% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-0.27 | $-0.28 | -3.7% | ✗ MISS |
Latest News
Aldeyra drops as FDA delays review of marketing application for lead drug
📉 NegativeSeeking Alpha•Dec 16, 2025, 12:34 PM
Reported Earlier, Aldeyra Therapeutics Receives PDUFA Extension For Reproxalap NDA Following FDA Request For Clinical Study Report
➖ NeutralBenzinga•Dec 16, 2025, 06:38 AM
Aldeyra Therapeutics Expands RASP Platform To Include Programs In Central Nervous System Diseases Associated With Inflammation; Updates Manufacturing Information On Reproxalap
📈 PositiveBenzinga•Nov 13, 2025, 12:24 PM
BTIG Reiterates Buy on Aldeyra Therapeutics, Maintains $9 Price Target
📈 PositiveBenzinga•Nov 10, 2025, 10:28 AM
Aldeyra Therapeutics Announces Statistically Significant Improvement In Liver Function In Patients Treated With ADX-629
📈 PositiveBenzinga•Oct 28, 2025, 11:13 AM
Aldeyra Wins EMA Orphan Drug Status for ADX-2191 to Treat Rare Eye Cancer
📈 PositiveBenzinga•Aug 28, 2025, 11:22 AM
Aldeyra Therapeutics Says FDA Grants Fast Track Designation For ADX-2191 For Treatment Of Retinitis Pigmentosa
📈 PositiveBenzinga•Aug 19, 2025, 11:05 AM
Frequently Asked Questions about ALDX
What is ALDX's current stock price?
Aldeyra Therapeutics, Inc. (ALDX) is currently trading at $4.96 per share. The stock has moved -1.00% today.
What is the analyst price target for ALDX?
The average analyst price target for ALDX is $7.00, based on 1 analyst.
What sector is Aldeyra Therapeutics, Inc. in?
Aldeyra Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALDX's market cap?
Aldeyra Therapeutics, Inc. has a market capitalization of $0.30 billion, making it a small-cap company.
Does ALDX pay dividends?
No, Aldeyra Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
ANRO
Alto Neuroscience, Inc.
$19.98
Mkt Cap: $0.6B
CADL
Candel Therapeutics, Inc.
$5.57
Mkt Cap: $0.3B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$11.74
Mkt Cap: $0.3B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to ALDX for comparison